about
Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infantsEarly (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infantsPentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infantsMethylxanthine treatment for apnoea in preterm infantsProphylactic methylxanthines for endotracheal extubation in preterm infantsProphylactic methylxanthine for prevention of apnoea in preterm infantsCarnitine supplementation for preterm infants with recurrent apnoeaProphylactic methylxanthines for extubation in preterm infantsCan the preterm lung recover from perinatal stress?Biomarkers for Bronchopulmonary Dysplasia in the Preterm InfantCaffeine therapy in preterm infantsAn update on pharmacologic approaches to bronchopulmonary dysplasiaPredictors of bronchopulmonary dysplasiaDrug-induced renal damage in preterm neonates: state of the art and methods for early detectionEarly Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-AnalysisRepresentative Sinusoids for Hepatic Four-Scale Pharmacokinetics SimulationsNeuroprotection by Caffeine in Hyperoxia-Induced Neonatal Brain InjuryAdenosine receptors as drug targets--what are the challenges?Clinical associations of immature breathing in preterm infants: part 1-central apnea.Effects of caffeine treatment for apnea of prematurity on cortical speech-sound differentiation in preterm infants.Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell's criteria?Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn ratsDiuretic exposure in premature infants from 1997 to 2011A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome.The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment.Reducing the incidence of chronic lung disease in very premature infants with aminophylline.Therapeutic effect of caffeine treatment immediately following neonatal hypoxic-ischemic injury on spatial memory in male rats.Neonatal resuscitation in low-resource settings: what, who, and how to overcome challenges to scale up?Methylxanthine treatment for apnea in preterm infants.Prophylactic methylxanthine for preventing of apnea in preterm infants.An adenosine A(2A) agonist injected in the nucleus of the solitary tract prolongs the laryngeal chemoreflex by a GABAergic mechanism in decerebrate pigletsFeasibility of comprehensive, unattended ambulatory polysomnography in school-aged childrenDrug therapy trials for the prevention of bronchopulmonary dysplasia: current and future targetsBronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung DiseasesAnti-inflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitisCaffeine for the management of apnea in preterm infants.A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.Apnea of prematurity: pathogenesis and management strategies.Apnea of prematurity: from cause to treatment
P2860
Q24187852-00DFB888-B589-4845-9E18-1EA0AEE89487Q24194710-4EB761C5-72A2-43B0-A250-AB391B0F7533Q24201869-81F2E091-0698-431F-BC78-83B7D7D53284Q24235661-5572150C-6A61-4EBD-B9F2-D22B867F4D5BQ24235753-60C3A914-A7F7-4326-AFF6-AF505AA24DB0Q24235779-220238F8-54A8-4D95-983D-7AB994AFB7E5Q24247700-9E55DAB0-389C-43D8-81B2-8C5F67773899Q24250229-8DFFB892-2C58-4F0E-B6C9-76A7635C8389Q26748643-6A0A3DDF-652D-416B-8A01-1B959446214BQ26750310-8D89E27B-E733-4FA3-98D0-0245034C3261Q26777204-AFC490C6-1B47-4874-9D88-9630B494E78DQ26825139-E1CF952A-62BB-45FB-A0DF-A02CA621F9D3Q26829843-C5649FDE-ACBA-4460-B841-6BC560DE6413Q26849339-8C4F7F65-F7BA-4791-9570-B1D403CA55CBQ28074483-6DBFCC9A-3D2A-4F18-9F22-A8ADBDC661F2Q28546872-FFC409EC-A951-427C-BC91-6CAABE8DE7D8Q29247914-3AE2EDC1-FA6B-4949-8983-21C652EE4C42Q29346491-FE69D2D4-C7CA-4491-830C-F4BD94CE8F53Q30277178-A9F94C40-DF69-40BF-B803-EC1BF1C32611Q30389736-4DD718BB-4AB7-4E36-BC8A-AAA5EB4C2A1DQ30443994-9B277FB4-5457-447F-8593-96544160AA92Q33378441-7E40E349-68C4-454B-AE6E-369EA8FEFA74Q33415111-F0ABFE53-1D41-465C-B531-A711C49D3302Q33517961-C714CB2E-4DC8-4D2C-8167-FAB64F38A5EDQ33545628-E4A8ED13-0BAC-478B-940F-D428994384CEQ33711647-F35BD6B6-40E6-4AEE-91D0-2B94E615BAB4Q33731016-1DEA847A-6369-4B85-A47C-E6BA376C0BC9Q33772048-A23ADF6C-6797-418E-8BF2-7943124385D7Q33871551-7066A7A1-027A-4E2D-9495-77B4DE03AC1AQ33907643-B6AC8612-A8D0-4BFA-9C42-CDC383B68488Q33907954-11F3D2C5-474E-4C99-8603-BDF77C4D4352Q33927683-A23BACFE-397D-4FBA-AB64-717C22E2A676Q33933789-32A1AEF0-60E0-422B-8391-124892F402BEQ33948552-91437F40-0329-49FA-8982-3A299312733BQ33956836-8ADC2416-81D4-4700-A7F4-F23219A32A47Q34008174-9793A639-F94B-4320-938F-F9C85AE555EEQ34029994-902A0B7D-CAFE-4E8D-A57F-C05DCDF84F6FQ34123512-3F100C24-4E5F-46F7-B0E2-B5CF69B6E00BQ34153141-2958D3E1-4358-4373-B131-F3D2B90EC5D0Q34163237-F6896B58-11AF-4A5D-86C2-D64AE01DE5B3
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Caffeine Therapy for Apnea of Prematurity
@ast
Caffeine Therapy for Apnea of Prematurity
@en
type
label
Caffeine Therapy for Apnea of Prematurity
@ast
Caffeine Therapy for Apnea of Prematurity
@en
prefLabel
Caffeine Therapy for Apnea of Prematurity
@ast
Caffeine Therapy for Apnea of Prematurity
@en
P2093
P3181
P356
P1476
Caffeine Therapy for Apnea of Prematurity
@en
P2093
Alfonso Solimano
Arne Ohlsson
Barbara Schmidt
Keith J. Barrington
Lex W. Doyle
Peter Davis
Robin S. Roberts
P304
P3181
P356
10.1056/NEJMOA054065
P407
P577
2006-05-18T00:00:00Z